$361 Million is the total value of Opaleye Management Inc.'s 53 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QURE | New | UNIQURE NV | $12,228,000 | – | 205,000 | +100.0% | 3.39% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $11,182,000 | – | 95,000 | +100.0% | 3.10% | – |
| NVTA | New | INVITAE CORP | $10,305,000 | – | 440,000 | +100.0% | 2.85% | – |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $9,308,000 | – | 1,825,000 | +100.0% | 2.58% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $7,697,000 | – | 105,000 | +100.0% | 2.13% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $7,543,000 | – | 1,900,000 | +100.0% | 2.09% | – |
| New | CYTOKINETICS | $6,877,000 | – | 850,000 | +100.0% | 1.90% | – | |
| HZNP | New | HORIZON PHARMA PLC | $4,890,000 | – | 185,000 | +100.0% | 1.35% | – |
| RTRX | New | RETROPHIN INC | $4,639,000 | – | 205,000 | +100.0% | 1.28% | – |
| CARA | New | CARA THERAPEUTICS INC | $3,924,000 | – | 200,000 | +100.0% | 1.09% | – |
| New | FORTRESS BIOTECH INC | $3,560,000 | – | 2,000,000 | +100.0% | 0.99% | – | |
| ACOR | New | ACORDA PHARMACEUTICALS | $3,522,000 | – | 265,000 | +100.0% | 0.98% | – |
| SWAV | New | SHOCKWAVE MED INC | $3,083,000 | – | 92,100 | +100.0% | 0.85% | – |
| LQDA | New | LIQUIDIA TECHNOLOGIES INC | $2,561,000 | – | 225,000 | +100.0% | 0.71% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS INC | $1,661,000 | – | 73,000 | +100.0% | 0.46% | – |
| ESTA | New | ESTABLISHMENT LABS HLDGS INC | $1,202,000 | – | 50,000 | +100.0% | 0.33% | – |
| THOR | New | SYNTHORX INC | $815,000 | – | 40,000 | +100.0% | 0.23% | – |
| FOMX | New | FOAMIX PHARMACEUTICALS LTD | $675,000 | – | 180,000 | +100.0% | 0.19% | – |
| KURA | New | KURA ONCOLOGY INC | $418,000 | – | 25,200 | +100.0% | 0.12% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL CO | $386,000 | – | 60,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 13F-HR/A | 2024-05-29 |
| 4 | 2024-05-23 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.